Search hospitals > Georgia > Macon
Gastroenterology Associates of Central Georgia, LLC
Claim this profileMacon, Georgia 31201
Global Leader in Crohn's Disease
Global Leader in Inflammatory Bowel Disease
Conducts research for Ulcerative Colitis
Conducts research for Ulcer
Conducts research for Esophagitis
62 reported clinical trials
1 medical researcher
Summary
Gastroenterology Associates of Central Georgia, LLC is a medical facility located in Macon, Georgia. This center is recognized for care of Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Esophagitis and other specialties. Gastroenterology Associates of Central Georgia, LLC is involved with conducting 62 clinical trials across 30 conditions. There are 1 research doctors associated with this hospital, such as Shahriar Sedghi, MD.Top PIs
Clinical Trials running at Gastroenterology Associates of Central Georgia, LLC
Crohn's Disease
Ulcerative Colitis
Inflammatory Bowel Disease
Ulcer
Esophagitis
Eosinophilic Esophagitis
Tulisokibart
for Crohn's Disease
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
Recruiting1 award Phase 31 criteria
Ozanimod
for Crohn's Disease
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.
Recruiting1 award Phase 33 criteria
Risankizumab
for Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely active CD in adult participants. Risankizumab is an approved drug for adults with CD. This study comprises of a Period A and a Period B. In Period A, participants are placed in 1 of 2 groups to receive either risankizumab SC or Placebo. In Period B, based on response, participants will receive risankizumab SC Dose B or Placebo. Participants who do not have improvement in CD symptoms at Week 12 will receive risankizumab SC Dose C and participants with worsening CD symptoms in period B will receive risankizumab SC. Approximately 276 adult participants with a diagnosis of moderately to severely active CD will be enrolled in approximately 250 sites globally. Participants will receive SC induction treatment of risankizumab or matching placebo for up to 24 weeks in Period A and B. The duration of the study will be approximately 49 weeks.
Recruiting1 award Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Gastroenterology Associates of Central Georgia, LLC?
Gastroenterology Associates of Central Georgia, LLC is a medical facility located in Macon, Georgia. This center is recognized for care of Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcer, Esophagitis and other specialties. Gastroenterology Associates of Central Georgia, LLC is involved with conducting 62 clinical trials across 30 conditions. There are 1 research doctors associated with this hospital, such as Shahriar Sedghi, MD.